Adimab Provides Year-End Update on 2021 Partnership Activities
Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that in 2021 it entered into agreements with 13 new companies. In addition, Adimab announced the expansion of 14 of its current partnerships and the achievement of 52 technical and development milestones across numerous collaborations.
Adimab has partnered with 95 companies for the discovery of therapeutic IgGs and bispecific antibodies. New alliances for 2021 include collaborations with 3T Biosciences, 76Bio, Inc., Adaptate Biotherapeutics, Celsius Therapeutics, Ikaika Therapeutics, Inc., Stellanova, and VVB, among others. In addition, Adimab expanded its collaborations with Adagio Therapeutics, Alector, Amagma, Innovent, iTeos, Link Immunotherapeutics, Mersana Therapeutics, Inc., NextPoint, Regeneron, Sensei Biotherapeutics, and Takeda, among others.
In 2021, Adimab and its partners initiated over 60 new therapeutic programs, bringing the total number of royalty-bearing programs to 425.
“We have reached a point where our reputation for quality and success drives our partnering interest,“ said Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. “Our discovery and engineering platform is completely unique from the rest of the industry and allows Adimab to generate the highest quality therapeutic molecules for our partners. In addition, we continue to develop new applications to provide additional solutions for IgGs, bispecifics, and cell-based therapeutic programs.”
“Getting to over 400 therapeutic programs was an important milestone for us in 2021. Unlike other providers in the industry, we take a deliberately conservative approach to our accounting – we only count programs that are royalty-bearing and where the discovery process has actually been initiated,” said Guy Van Meter, Chief Business Officer of Adimab.
Adimab is the leading provider of therapeutic antibody discovery and engineering technologies. This includes naïve discovery from synthetic libraries in yeast or B cells (mice and humans), antibody engineering and optimization, multi-specific antibody engineering, and a portfolio of proprietary CD3 antibodies licensed non-exclusively for bispecific applications. Adimab focuses solely on its partners and not on developing an internal product pipeline. Since 2009, Adimab has partnered with 95 pharmaceutical and biotechnology companies, generating 425 therapeutic programs, over 50 clinical programs, and its first approved product. The Adimab technology has been transferred and implemented at Biogen, GSK, Lilly, Merck, Novo Nordisk, and Takeda. Funded discovery partners include leading pharmaceutical companies, such as Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Regeneron, Sanofi, Takeda and others. Adimab has also partnered with many early-stage venture-backed companies, including Amagma, Cygnal, Dragonfly, iOmx, NextPoint, Pliant, Tizona, TRex Bio and others, as well as mid-size public biopharmaceutical companies such as Acceleron, Alector, Cullinan Oncology, Innovent, Jounce, Mersana, Scholar Rock, Surface Oncology, and others.
Adimab’s integrated antibody discovery and engineering platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most demanding standards for affinity, epitope coverage, species cross-reactivity, and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.
Guy Van Meter
Chief Business Officer